Brief: Sumitomo Dainippon Pharma, SanBio Say Phase 2B Study In U.S. Evaluating SB623 Did Not Meet Primary Endpoint
29/01/2019 06:12
Jan 29 (Reuters) - JAPAN'S SUMITOMO DAINIPPON PHARMA CO LTD
4506.T AND SANBIO CO LTD 4592.T SAY:
* PHASE 2B STUDY CONDUCTED IN U.S. EVALUATING REGENERATIVE
CELL
MEDICINE SB623 DID NOT MEET ITS PRIMARY ENDPOINT
* WILL CONSIDER FUTURE DEVELOPMENT PLANS OF SB623 BASED ON
ADDITIONAL ANALYSES OF STUDY RESULTS
Source text for Eikon: ID:nTSMc7184e
Further company coverage: 4506.T 4592.T
(Reporting By Chris Gallagher)
((chris.gallagher@thomsonreuters.com;))